Glenmark Pharmaceuticals has cut price of antiviral drug Favipiravir --sold under the brand name FabiFlu for the treatment of patients with mild to moderate COVID-19 by 27 percent to Rs 75 per tablet. The company had launched the drug in June at a price of Rs 103 per tablet.
The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark's facilities in India, the benefits of which are being passed on to patients in the country.
Glenmark Pharmaceuticals is a global researchled pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
